Page last updated: 2024-11-05

thalidomide and Colitis

thalidomide has been researched along with Colitis in 21 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.

Research Excerpts

ExcerptRelevanceReference
"To observe the effects of thalidomide on 2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced experimental colitis in rats and to explore the possible mechanism of thalidomide in the treatment of CD."7.96Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells. ( Jin, S; Li, D; Luan, X; Tian, F; Xie, Y; Yan, B, 2020)
"Thalidomide was effective in the management of TNBS-induced colitis in young rats."7.80Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014)
"To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis."7.74Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. ( Carneiro, AJ; Carvalho, AT; Carvalho, J; Castelo-Branco, M; Dines, I; Elia, C; Madi, K; Pereira Junior, FA; Pereira, MG; Rocha, E; Schanaider, A; Silv, F; Souza, H; Tortori, C, 2007)
" The aim of the present study was to examine the effects of thalidomide treatment in the development of experimental colitis."7.73Thalidomide treatment reduces colon injury induced by experimental colitis. ( Cuzzocrea, S; De Sarro, A; Di Paola, R; Genovese, T; Mazzon, E; Muià, C, 2005)
" Thus, the aim of the present study was to examine the effects of thalidomide treatment on the permeability and structure of small intestine TJs in an animal model of experimental colitis induced by dinitrobenzene sulfonic acid (DNBS)."7.73Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. ( Cuzzocrea, S; Mazzon, E, 2006)
"To evaluate the effects of thalidomide in a model of experimental colitis."7.71Amelioration of experimental colitis by thalidomide. ( Aeed, H; Avni, Y; Bruck, R; Hershkoviz, R; Kenet, G; Shirin, H; Wardi, J; Zaidel, L, 2001)
"A 35-year-old male patient, known in our department since 1979 on account of a severe and complete Behçet's syndrome, was treated with thalidomide (CG-217) as a final pharmacological measure to avoid colectomy during a severe attack of Behçet colitis."7.68Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). ( Larsson, H, 1990)
" Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized."5.91Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023)
"Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy."5.35Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008)
"Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing."5.29Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996)
"Ten patients with therapy refractory IBD (nine Crohn's disease, one ulcerative colitis) received thalidomide 300 mg daily in a 12 week open label study."5.10Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. ( Bauditz, J; Lochs, H; Wedel, S, 2002)
"Eleven patients (nine males, mean age 33 years, range 20-77 years) with chronic inflammatory bowel disease (six Crohn's disease (CD), four ulcerative colitis (UC), one indeterminate colitis (IC)) who were symptomatic despite standard medical therapy were administered a daily dose of thalidomide for 12 weeks in an open-labeled protocol."5.10Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. ( Bariol, C; Byrnes, DJ; Edwards, PD; Field, A; Hing, M; Meagher, AP; Vickers, CR; Wettstein, AR, 2002)
"Thalidomide was effective in the management of TNBS-induced colitis in young rats."3.80Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014)
" Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)."3.79Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013)
"TNBS-induced colitis increased seizure susceptibility to a subconvulsive dose of pentylenetetrazole; the immunomodulator thalidomide was protective."3.75Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model. ( Avti, PK; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A, 2009)
" Thalidomide is effective in reducing the extent of arthritis as well as reducing the seizure scoring and increasing seizure onset in the adjuvant arthritis group."3.74Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat. ( Arora, SK; Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS; Saikia, UN; Toor, JS, 2008)
"To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis."3.74Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. ( Carneiro, AJ; Carvalho, AT; Carvalho, J; Castelo-Branco, M; Dines, I; Elia, C; Madi, K; Pereira Junior, FA; Pereira, MG; Rocha, E; Schanaider, A; Silv, F; Souza, H; Tortori, C, 2007)
" The aim of the present study was to examine the effects of thalidomide treatment in the development of experimental colitis."3.73Thalidomide treatment reduces colon injury induced by experimental colitis. ( Cuzzocrea, S; De Sarro, A; Di Paola, R; Genovese, T; Mazzon, E; Muià, C, 2005)
" Thus, the aim of the present study was to examine the effects of thalidomide treatment on the permeability and structure of small intestine TJs in an animal model of experimental colitis induced by dinitrobenzene sulfonic acid (DNBS)."3.73Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. ( Cuzzocrea, S; Mazzon, E, 2006)
"To evaluate the effects of thalidomide in a model of experimental colitis."3.71Amelioration of experimental colitis by thalidomide. ( Aeed, H; Avni, Y; Bruck, R; Hershkoviz, R; Kenet, G; Shirin, H; Wardi, J; Zaidel, L, 2001)
"A 35-year-old male patient, known in our department since 1979 on account of a severe and complete Behçet's syndrome, was treated with thalidomide (CG-217) as a final pharmacological measure to avoid colectomy during a severe attack of Behçet colitis."3.68Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). ( Larsson, H, 1990)
" Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized."1.91Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023)
"Thalidomide was used as treatment in colitis and arthritis group, whereas etoricoxib was used in CWG group."1.36Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models. ( Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS, 2010)
"Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy."1.35Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008)
"Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing."1.29Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (9.52)18.2507
2000's13 (61.90)29.6817
2010's4 (19.05)24.3611
2020's2 (9.52)2.80

Authors

AuthorsStudies
Meng, Z3
Fu, B3
Yang, Z3
Xu, Y3
Huang, H3
Bai, Y3
Fang, X3
Shen, S3
Yang, J3
Yong, J3
Tao, X3
Ma, C3
Miao, W3
Ren, H3
Wang, Y3
Xu, H3
Li, X3
Xie, Y1
Li, D1
Luan, X1
Jin, S1
Yan, B1
Tian, F1
Zitomersky, NL1
Levine, AE1
Atkinson, BJ1
Harney, KM1
Verhave, M1
Bousvaros, A1
Lightdale, JR1
Trenor, CC1
Fakhoury, M1
Coussa-Charley, M1
Al-Salami, H1
Kahouli, I1
Prakash, S1
Xu, J1
Zheng, C1
Huang, Y1
Liang, Y1
Rao, RS2
Medhi, B3
Saikia, UN1
Arora, SK1
Toor, JS1
Khanduja, KL3
Pandhi, P2
Sokol, H1
Suarez, F1
Meatchi, T1
Malamut, G1
Pocidalo, MA1
Blanche, S1
Cellier, C1
Hermine, O1
Prakash, A1
Avti, PK1
Chakrabarti, A1
Mazzon, E2
Muià, C1
Di Paola, R1
Genovese, T1
De Sarro, A1
Cuzzocrea, S2
Kirkham, SE1
Lindley, KJ1
Elawad, MA1
Blanshard, C1
Shah, N1
Chidlow, JH1
Langston, W1
Greer, JJ1
Ostanin, D1
Abdelbaqi, M1
Houghton, J1
Senthilkumar, A1
Shukla, D1
Mazar, AP1
Grisham, MB1
Kevil, CG1
Carvalho, AT1
Souza, H1
Carneiro, AJ1
Castelo-Branco, M1
Madi, K1
Schanaider, A1
Silv, F1
Pereira Junior, FA1
Pereira, MG1
Tortori, C1
Dines, I1
Carvalho, J1
Rocha, E1
Elia, C1
Johnson, L1
Jarvis, JN1
Wilkins, EG1
Hay, PE1
Postema, PT1
den Haan, P1
van Hagen, PM1
van Blankenstein, M1
Lienenlüke, B1
Stojanovic, T1
Fiebig, T1
Fayyazi, A1
Germann, T1
Hecker, M1
Kenet, G1
Wardi, J1
Avni, Y1
Aeed, H1
Shirin, H1
Zaidel, L1
Hershkoviz, R1
Bruck, R1
Bauditz, J1
Wedel, S1
Lochs, H1
Bariol, C1
Meagher, AP1
Vickers, CR1
Byrnes, DJ1
Edwards, PD1
Hing, M1
Wettstein, AR1
Field, A1
Larsson, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195]Phase 262 participants (Anticipated)Interventional2020-12-14Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for thalidomide and Colitis

ArticleYear
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
    Gut, 2002, Volume: 50, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Colitis, Ulcerative; Crohn Disease; Dose-

2002
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.
    Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:2

    Topics: Adult; Aged; Colitis; Colitis, Ulcerative; Colonoscopy; Crohn Disease; Female; Humans; Immunosuppres

2002

Other Studies

19 other studies available for thalidomide and Colitis

ArticleYear
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf

2023
Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Animals; Colitis; Colon; Rats; Rats, Sprague-Dawley; Th17 Cells; Thalidomide; Trinitrobenzenesulfoni

2020
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli

2013
Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice.
    Current drug delivery, 2014, Volume: 11, Issue:1

    Topics: Alginates; Animals; Anti-Inflammatory Agents; Biomarkers; Capsules; Chemistry, Pharmaceutical; Colit

2014
Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism.
    Chinese medical journal, 2014, Volume: 127, Issue:12

    Topics: Animals; Colitis; Cytokines; Inflammatory Bowel Diseases; Interleukin-10; Interleukin-1beta; NF-kapp

2014
Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:10

    Topics: Acetic Acid; Analysis of Variance; Animals; Arthritis; Colitis; Cyclooxygenase Inhibitors; Cytokines

2008
Thalidomide as a treatment for refractory CGD colitis.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:4

    Topics: Biopsy; Colitis; Diagnosis, Differential; Follow-Up Studies; Granulomatous Disease, Chronic; Humans;

2009
Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model.
    The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:10

    Topics: Animals; Brain; Catalase; Colitis; Colon; Disease Models, Animal; Female; Glutathione Peroxidase; Li

2009
Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models.
    Fundamental & clinical pharmacology, 2010, Volume: 24, Issue:3

    Topics: Animals; Arthritis, Experimental; Colitis; Disease Models, Animal; Granuloma; Inflammation; Lipid Pe

2010
Thalidomide treatment reduces colon injury induced by experimental colitis.
    Shock (Augusta, Ga.), 2005, Volume: 23, Issue:6

    Topics: Animals; Colitis; Colon; Cytokines; Disease Models, Animal; Immunohistochemistry; Immunosuppressive

2005
Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis.
    Shock (Augusta, Ga.), 2006, Volume: 25, Issue:5

    Topics: Animals; Colitis; Dinitrobenzenes; Disease Models, Animal; Fluorescent Antibody Technique, Indirect;

2006
Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide.
    Journal of pediatric gastroenterology and nutrition, 2006, Volume: 42, Issue:5

    Topics: Angiodysplasia; Angiogenesis Inhibitors; Angiography; Blood Transfusion; Capsule Endoscopy; Child; C

2006
Differential angiogenic regulation of experimental colitis.
    The American journal of pathology, 2006, Volume: 169, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; CD4-Positive T-Lymphocytes; Colitis; Colon; Disease

2006
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.
    World journal of gastroenterology, 2007, Apr-21, Volume: 13, Issue:15

    Topics: Animals; CD4-Positive T-Lymphocytes; Colitis; Colon; Gene Expression Regulation; Immunosuppressive A

2007
Thalidomide treatment for refractory HIV-associated colitis: a case series.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jul-01, Volume: 47, Issue:1

    Topics: Adult; Colitis; Colon; Colonoscopy; HIV Infections; Humans; Immunosuppressive Agents; Intestinal Muc

2008
Treatment of colitis in Behçet's disease with thalidomide.
    European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:9

    Topics: Adult; Behcet Syndrome; Colitis; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, B

1996
Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction.
    British journal of pharmacology, 2001, Volume: 133, Issue:8

    Topics: Animals; CD40 Ligand; Cell Adhesion; Colitis; Colon; Endothelium; Gene Expression Regulation; Humans

2001
Amelioration of experimental colitis by thalidomide.
    The Israel Medical Association journal : IMAJ, 2001, Volume: 3, Issue:9

    Topics: Alkylating Agents; Animals; Colitis; Immunosuppressive Agents; Iodoacetamide; Rats; Thalidomide; Tum

2001
Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217).
    Journal of internal medicine, 1990, Volume: 228, Issue:4

    Topics: Adult; Behcet Syndrome; Colitis; Humans; Male; Thalidomide

1990